Impact of Timing of Achievement of Red Blood Cell-Transfusion Independence (RBC-TI) on Clinical Outcomes and Resource Utilization in Lower-Risk Myelodysplastic Syndromes (LR-MDS)

被引：0

作者：

Coughlan, Anna ^{[1
]}

Klijn, Sven L. ^{[2
]}

Xiao, Hong ^{[3
]}

White, Benjamin ^{[4
]}

Litkiewicz, Michal ^{[5
]}

Kadambi, Ananth ^{[4
]}

Sichevaya, Alina

Hnoosh, Ahmed ^{[6
]}

Miteva, Dimana ^{[7
]}

Yucel, Aylin ^{[3
]}

机构：

[1] Evidera, Bethesda, MD USA

[2] Bristol Myers Squibb, Lawrence, NJ USA

[3] Bristol Myers Squibb, Princeton, NJ USA

[4] Evidera, San Francisco, CA USA

[5] Evidera, London, England

[6] Evidera, London, England

[7] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

myelodysplastic syndromes; transfusion independence; burden of illness;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MDS-008

引用

页码：S351 / S351

页数：1

共 50 条

[21] Evaluating the Impact of an Electronic Medical Record (EMR) Alert on Appropriate Dosing of Luspatercept in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Community Oncology Network
Singh, Nisha
Peters, Brooke
Chang, Melody
Maksour, Manale
McMullen, Nicole
Winegar, Bradley
Perkey, Cassandra
Gavrilov, Svetlana
Swanson, Ashley
Slaff, Samantha
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S389 - S390
[22] Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndrome (LR-MDS) Is Associated with Better Survival: A Population Level Analysis Based on a Large US Health Insurance Claims Database
Komrokji, Rami S.
Sengupta, Nishan
Supina, Dylan
Navada, Shyamala
Potluri, Ravi
Tyagi, Rohit
Werwath, Tim
Xie, Zhuoer
Padron, Eric
Sallman, David A.
BLOOD, 2023, 142
[23] Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents
Garcia-Manero, Guillermo
Matsuno, Rayna K.
McBride, Ali
Mohammed, Hina
Idryo, Danny
Broome, Ronda
Herriman, Autumn
Johnson, Tiffany
Wilkinson, Kristiana
Schrag, Andrew
Johanson, Colden
Izano, Monika
Makinde, Adeola
Mukherjee, Sudipto
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (09): : e283 - e292
[24] Luspatercept Versus Epoetin Alfa (EA) for Treatment of Anemia in Patients With Erythropoiesis-Stimulating Agent (ESA)-Naive Lower-Risk Myelodysplastic Syndromes (LR-MDS) Requiring Red Blood Cell (RBC) Transfusions: Data from the Phase III COMMANDS Study
Garcia-Manero, Guillermo
Platzbecker, Uwe
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Zhang, Jennie
Giuseppi, Ana Carolina
Kreitz, Sandra
Pozharskaya, Veronika
Keeperman, Karen L.
Rose, Shelonitda
Shetty, Jeevan K.
Hayati, Sheida
Vodala, Sadanand
Degulys, Andrius
Paolini, Stefania
Cluzeau, Thomas
Della Porta, Matteo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S355 - S356
[25] Roxadustat (FG4592; ASP1517; AZD9941) in the Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (LR-MDS) and Low Red Blood Cell (RBC) Transfusion Burden (LTB)
Henry, David H.
Glaspy, John
Harrup, Rosemary Anne
Mittelman, Moshe
Zhou, Amy
Bradley, Charles
Saha, Gopal
Bartels, Pamela
Robert, Leong
Yu, Kin-Hung P.
BLOOD, 2019, 134
[26] Sustained Erythroid Response Associated With Red Cell Transfusion and Progressive Growth Factor Independence Is Feasible With Adjuvant Sertraline In Low-Risk Myelodysplastic Syndrome (LR-MDS)
Li, Rui
Zheng, Matthew
Yellapragada, Sarvari Venkata
Perez, Ruben Hernandez
Mims, Martha
Rivero, Gustavo A.
BLOOD, 2013, 122 (21)
[27] Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q
List, A. F.
Giagounidis, A.
Backstrom, J. T.
Fu, T.
Fenaux, P.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[28] Association of Clinical Characteristics at Diagnosis with Outcomes in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Erythropoiesis Stimulating Agents (ESAs): Findings from a Real-World Medical Chart Review in the US
Mukherjee, Sudipto
Savill, Kristin M.
Gajra, Ajeet
Gentile, Danielle
Falkenstein, Angelica
Miller, Talia
Laney, JaLyna
McBride, Ali
BLOOD, 2022, 140 : 10998 - 11000
[29] The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry
Buckstein, Rena
Chodirker, Lisa
Yee, Karen W. L.
Geddes, Michelle
Leitch, Heather A.
Christou, Grace
Banerji, Versha
Leber, Brian
Khalaf, Dina
St-Hilaire, Eve
Finn, Nicholas
Nevill, Thomas
Keating, Mary-Margaret
Storring, John
Parmentier, Anne
Thambipillai, Aksharh
Tang, Derek
Westcott, Christopher
Cameron, Chris
Spin, Paul
LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 651 - 661
[30] Impact of Red Blood Cell Transfusion Intensity on Progression-Free Survival in Lower-Risk MDS Patients Included in the European Leukemianet MDS Registry
De Swart, Louise
Crouch, Simon
Hoeks, Marlijn
Smith, Alex
Langemeijer, Saskia
Fenaux, Pierre
Symeonidis, Argiris
Cermak, Jaroslav
Stauder, Reinhard
Mittelman, Moshe
Sanz, Guillermo
Hellstrom-Lindberg, Eva
Malcovati, Luca
Holm, Mette Skov
Germing, Ulrich
Madry, Krzysztof
de Almeida, Antonio Medina
Tatic, Aurelia
Savic, Aleksandar
Gredelj-Simec, Njetocka
Bresler, Agnes Guerci
Culligan, Dominic
Itzykson, Raphael
Beyne-Rauzy, Odile
Park, Sophie
van Marrewijk, Corine
Blijlevens, Nicole M. A.
Bowen, David T.
de Witte, T. M.
BLOOD, 2017, 130

← 1 2 3 4 5 →